Advances in the development of biologics to treat drug addictions and overdose.
Drug addictions are complex disorders that require multiple approaches, including the use of pharmacotherapies. Currently, these therapies are based on "small" molecules or chemicals that penetrate the blood-brain barrier, reach the brain, and produce their effects on neurotransmitter systems. Unfortunately, they often do not have the desired efficacy or may cause undesirable side effects, especially at the central nervous system (CNS) level. A novel approach is the use of biologics to treat drug addictions. Biologics are usually complex and "large" molecules, which do not cross the blood-brain barrier and, thus, have no CNS effects. In principle, it appears that the efficacy of biologics to treat drug addiction is by preventing the access of the drug of abuse to the brain, preventing the activation of brain reward systems, and eventually producing the extinction of addiction. Biologic therapeutics includes immunotherapies, such as vaccines or antibodies, as well as enzymes. New products as well as new and more efficient methods of production, are offering vast opportunities to advance the discovery and development of biologics to treat addictions as well as drug overdose. These products include new vaccines with greater specificity and ability to produce antibodies, new methods and techniques to produce vaccines and antibodies, as well as new enzymes with high efficiency to metabolize cocaine. The purpose of the article is to provide a general overview of the development of biologics for the treatment of drug addictions and overdose.
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, USA. imontoya@mail.nih.gov
Iván D
ID
Montoya
D000701:Analgesics, Opioid / Q000506:poisoning; D001688:Biological Products / Q000627:therapeutic use*; D003042:Cocaine / Q000506:poisoning; D019970:Cocaine-Related Disorders / Q000188:drug therapy; D062787:Drug Overdose / Q000188:drug therapy*; D006801:Humans; D009293:Opioid-Related Disorders / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy*
D000701:Analgesics, Opioid; D001688:Biological Products; D003042:Cocaine